Patenting the genes of marine creatures and why it could matter for research

| | June 18, 2018
Dfa PjkX AE TB
Image credit: National Oceanic and Atmospheric Administration
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

From the tiniest microbe to the biggest whale, the ocean is teeming with life. For corporations and researchers, that biodiversity is a veritable gold mine of genetic potential.

[Robert] Blasiak is the first author of a new paper, out [June 6] in the journal Science Advances, that charts currently-held patents on marine genetic resources. That paper’s findings paint a strange picture: of the almost 13,000 genetic patents held on marine species, almost half are held by a single corporation.

In this case, for a company that has patented a gene from a sea organism (known as a Marine Genetic Resource), owning the patent to a particular genetic sequence allows them the sole right to do research on it and produce products related to it.

Related article:  When is it ok to edit the genome of a human embryo? Americans have mixed opinions

The concerns with gene patenting are that giving corporations control of the literal code of life inherently devalues that life, and that lack of free access to genetic information could impede research and development of novel things like cancer treatments.

This September, the United Nations will begin negotiating a new treaty to regulate the high seas that will explicitly include MGRs. The negotiations are expected to stretch into 2020. Blasiak says he and his colleagues would like to see BASF, the corporation that holds holds 47 percent of the MGR patents, take a seat at the table.

Read full, original post: The genes of many marine creatures are patented—and one company owns half of them

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend